Table 1.
Differentiation capacity | Isolated cells | Origins & methods | Advantages | Disadvantages |
---|---|---|---|---|
Pluripotency | ESCs | 1. Blastocyst; inner cell mass | ● Differentiation into three germ layers | ● Immunological concerns |
2. Somatic cell nuclear transfer (SCNT) | ● Self-renewal and high replication | ● Ethical debate | ||
● Approved by US FDA | ● Potential for teratoma | |||
iPSCs | Reprogramming of somatic cells by gene transfer | ● Less ethical concerns than ESCs | ● Need method standardization | |
● Patient-specific | ● Potential for teratoma | |||
● Autologus | ● Validation for safety | |||
Multipotency | ASCs | Bone marrow, adipose tissue, umblical cord, amniotic fluid, placenta, CNS | ● Less ethical concerns than ESCs and IPSCs | ● Less cell proliferation |
● Limit differentiation potencial |
ESCs : embryonic stem cells, US FDA : United States Food and Drug Administration, iPSCs : induced pluripotent stem cells, ASCs : adult stem cells, CNS : central nervous system